

Feasibility of Using Infant Testing during Immunization to Estimate Mother-to-Child-Transmission Rates in Zambia

Joseph Simbaya (✉ j.simbaya@unza.zm)

<https://orcid.org/0000-0001-7518-6370>

Patricia Funjika

University of Zambia, Institute of Economic and Social Research

Arthur Moonga

University of Zambia Institute of Economic and Social Research

John Mwale

National AIDS Council

Chipepo Kankasa

University Teaching Hospital, Pediatric HIV Centre of Excellence

Research article

Keywords: HIV, Mother-to-child transmission, Africa, Children

Posted Date: March 16th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-17305/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

RESEARCH

Feasibility of Using Infant Testing during Immunization to Estimate Mother-to-Child-Transmission Rates in Zambia

Joseph Simbaya^{1*}, Patricia Funjika¹, Arthur Moonga², John Mwale³ and Chipepo Kankasa⁴

*Correspondence:

j.simbaya@unza.zm

¹Institute of Economic and Social Research (University of Zambia), Munali Road, 10101 Lusaka, Zambia

Full list of author information is available at the end of the article

Abstract

Background: This study piloted the feasibility of infant testing in immunization services as a strategy for estimating MTCT rates among the population of HIV exposed infants at national and subnational levels in Zambia.

Methods: The study recruited a cross-sectional nationally representative sample of 8,042 caregiver-baby pairs in 38 high volume immunization sites in 7 towns across 3 provinces of Zambia. All mothers who brought their children below the age of one year for immunization at the study facilities were invited to participate in the study. All consenting mothers were interviewed and blood drawn from their babies for; rapid HIV antibody test to determine exposure and DNA PCR test for samples of all HIV-exposed babies to determine HIV infection.

Results: Of 8,042 recruited caregiver-baby pairs, 1,407 (17.5 %) babies were HIV-exposed. More than 90 percent of all mothers of HIV exposed infants reported that they attended ANC visits more than two times and facility based deliveries stood at 92 percent. Exclusive breastfeeding among HIV exposed infants reduced with increase in age of infant; it was highest at 6 weeks (82 %) followed by 10 weeks (74 %), 14 weeks (74 %) and 9 months (4 %). MTCT rates were relatively lower than what was reported before in subnational studies and stood at 4.94 percent among Penta 1 seekers, 3.08 percent among Penta 2 seekers, 2.63 percent among Penta 3 seekers and 5.15 percent among Measles vaccination seekers. The overall MTCT rate stood at 4.05 percent. About 46 percent of HIV positive babies were male compared to 54 percent females. Babies of mothers below the age of 25 years accounted almost half (47 %) of all HIV infected babies in the study. Reported exclusive breastfeeding among HIV positive babies was 79 percent for Penta 1 seekers, 78 percent for Penta 2 seekers and 100 percent for Penta 3 seekers.

Conclusion: The study succeeded in estimating the MTCT rates using infant testing in immunization services, thereby demonstrating that it is feasible to use routine infant testing in immunization services as a strategy for estimating MTCT rates among the population of HIV-exposed infants in Zambia.

Keywords: HIV; Mother-to-child transmission; Africa; Children

Background

- 1 Vertical transmission of Human Immunodeficiency Virus (HIV) is the most common
- 2 source of paediatric HIV infection in Zambia [1]. In 2016, around 8,900 children
- 3 became newly infected with HIV in Zambia indicating a 56 percent decline from
- 4 20,000 new paediatric infections in 2009 [2, 3]. Mother-to-Child Transmission of HIV

(MTCT) ranges from 15 percent to 45 percent in the absence of any intervention. MTCT can however be reduced to below 5 percent with effective interventions during pregnancy, labour, delivery and breastfeeding. Interventions include inter alia; Antiretroviral Treatment (ART) for the HIV positive pregnant woman or mother and a short course of antiretroviral drugs for the exposed infant, facility based delivery, and appropriate breastfeeding practice [4, 5].

Zambia first introduced its rigorous Prevention of Mother-to-Child Transmission of HIV (PMTCT) programme in 1999 and has been committed to virtual elimination of MTCT since 2010 [6]. Zambia's prevention and treatment of HIV infection guidelines requires the testing of all women receiving Antenatal Care (ANC) and enrolment of all those that are found positive into HIV care and treatment [7].

Despite Zambia's continued efforts to eliminate MTCT, measuring of MTCT at national level remains a challenge despite the routine documentation of infant testing data through the PMTCT programme. Previous studies on efficacy of routine HIV testing data from PMTCT programmes have indicated that the data is largely unavailable and when it is available, it is usually incomplete, inaccurate and not available on time [8, 9, 10, 11, 12], thus partly explaining the reluctance to use it for estimating MTCT rates. Previous efforts to measure MTCT rates have therefore primarily focused on subnational levels.

Measurement of MTCT is critical in planning and meeting the needs of paediatric HIV prevention, care, and treatment services for children, as well as evaluating the effectiveness of PMTCT interventions [13, 14]. The Government of the Republic of Zambia and the international community are cognizant of the challenge in measuring MTCT. This study was therefore conducted with the aim of assessing the feasibility of infant testing in immunization services as a strategy for estimating MTCT rates among the population of HIV exposed infants (HEI).

The Zambia Programme on Immunization seeks to immunize infants against:

- Tuberculosis with the Bacille Calmette Guerin (BCG) vaccine at birth;
- Polio with oral polio vaccine (OPV) at 0 (birth), 6, 10 and 14 weeks and inactivated polio vaccine (IPV) at 14 weeks;
- Diphtheria, Pertussis, Tetanus, Haemophilus Influenza type B, Hepatitis B with three doses of the Penta vaccine at 6, 10 and 14 weeks of age (DPTHibHep1, DPTHibHep2 and DPTHibHep3 respectively);
- Diarrhoea with Rota vaccine at 6 and 10 weeks;
- Streptococcal Pneumonia with the pneumococcal conjugate vaccine (PCV) at 6, 10 and 14 weeks
- Measles and Rubella vaccines at 9 and 18 months of age;

HIV testing for HEI in Zambia is aligned to immunization and is done at birth (during BCG and OPV), 6 weeks (during OPV, DPT1 and Rota), 14 weeks (during OPV, IPV, and PCV), 9 months (during Measles and Rubella), 12 months, 18 months (during measles and rubella), and 24 months [7]. This study was guided by immunization service statistics which suggest that client flow is fairly evenly divided among the three Penta vaccines and Measles vaccine, with the highest proportion at DPTHibHep1 and the lowest at measles.

49 **Methods**

50 This was a variant of sentinel surveillance study which followed a cross-sectional
51 approach. The study took advantage of Zambia's highly successful childhood im-
52 munization program which starts at birth (BCG) through to 18 months (measles
53 and rubella). Using these services, the study recruited mothers and infants for HIV
54 testing to provide data for measuring the MTCT rates. The study sought to obtain
55 blood samples from 8,000 infants under the age of 12 months distributed across
56 38 health facilities from across three provinces (Copperbelt, Lusaka and Southern
57 provinces of Zambia). It was estimated that this would yield a nationally represen-
58 tative sample of approximately 1,240 HEI.

59 The nationally representative sample of 1,240 was determined using an average
60 HIV prevalence among women 15-49 of 21.6% in 2007 [15] and adjusting for lower
61 prevalence among pregnant women than non-pregnant women (11.6% vs. 16.6%
62 nationally) and the pregnancy rate (8% currently pregnant), it was estimated that
63 15.5% of women with a recent birth are HIV-positive. Assuming no differential
64 mortality, equal likelihood of seeking vaccination and equal refusal rates, 1,240
65 (15.5%) out of 8,000 infants tested would be HIV-exposed. The precision of the
66 estimated age-specific MTCT rates would depend on the age distribution of HIV-
67 exposed infants in the sample.

68 In light of national vaccination norms promoting Penta vaccine booster shots
69 (Penta-2 and Penta-3) at 4-week intervals, data collection at any one vaccination
70 site was limited to a 4-week period to avoid re-peat testing of infants. Participants
71 were concurrently recruited at all vaccination sites in the study until a total sample
72 of 8,000 consenting participants was achieved.

73 During the data collection period, all consenting caregivers of infants between 0
74 and 12 months of age who were receiving vaccinations in study sites were recruited.
75 Inclusion criteria for care-givers were: Caregiver of age 16 and over, attending vac-
76 cination for DPT1, DPT2, DPT3 or measles with infants younger than 12 months
77 of age; and physically and mentally capable of providing informed consent for the
78 interview.

79 This study involved interviewing the caregivers and taking blood samples from
80 participating infants and testing them for both HIV antibodies (all recruited infants)
81 and HIV DNA (infants with positive antibody tests). As part of obtaining informed
82 consent, all caregivers were informed about the need for and difference between the
83 two tests and that the presence of HIV antibodies in the baby's blood meant that
84 the mother was HIV-positive. However, anti-body test results were only availed
85 to the caregivers on request and upon receiving adequate counselling. For quality
86 assurance and infant safety purposes, the study used certified HIV counsellors and
87 Nurses working at the respective health facility with experience in DBS collection.
88 All study counsellors and nurses received additional training from the research team
89 to ensure that they had the knowledge and skills to educate mothers about the
90 testing procedures and to properly take and preserve infant blood samples. To
91 avoid irritating the child, only one sample was drawn from which an antibody test
92 was done to determine exposure as well as DBS to determine actual HIV infection.

93 The MTCT rate was calculated as a proportion of infant blood samples with a
94 positive PCR test result among infants with a positive HIV antibody test result

95 or with known HIV-positive mothers; the numerator was the number of all PCR
96 positive babies and the denominator was the number of all HIV exposed infants.

97 **Results**

98 **Study Population**

99 The population for the study encompassed all caregiver-infant pairs attending im-
100 munisation for Penta vaccine 1, to 3, and measles vaccine for 9 months at the study
101 sites. Of the 8,522 caregiver-infant pairs that were approached, 8,289 pairs consented
102 for interviews and 8,042 consented for infant HIV testing representing a 97.27 per-
103 cent and 94.37 percent response rates for interviews and infant testing respectively
104 as shown in Table 1. Copperbelt province had the highest interview response rate
105 (98.59%) followed by Southern (97.04%) and Lusaka (96%) provinces and there was
106 an almost equal distribution of infant testing response across provinces.

107 Table 1 further shows that Southern province recruited the highest number of
108 participants (2,960) followed by Copperbelt (2,713) and Lusaka (2,369). A total of
109 seven districts participated in the study; Ndola, Kitwe and Chingola from Copper-
110 belt Province, Livingstone, Choma, and Mazabuka from Southern Province, and
111 Lusaka from Lusaka Province.

112 **TABLE 1 HERE**

113 **Social demographics**

114 Male babies accounted for about 52 percent of the sample while female babies
115 accounted for about 48 percent (Figure 1). Overall, slightly more babies recruited
116 for the study came to the facility to receive Penta 1 (27 %). The rest came for Penta
117 2 (23 %), Penta 3 (25 %) and Measles (26 %).

118 **FIGURE 1 HERE**

119 The majority (47 %) of the mothers were aged less than 25 years old. Similarly,
120 the majority were married (82 %), had secondary education (62 %) and were not
121 employed (67 %) (Table 2).

122 **TABLE 2 HERE**

123 **HIV Infant Exposure**

124 The HEI accounted for 17.5 percent of the overall infants tested for HIV antibody.
125 Slightly more male infants (10 %) were HIV exposed than females (8 %). Of all
126 HEI (N=1,409), more male babies (56 %) were exposed than female babies (44 %).
127 Slightly below half (45 %) of all HEI had mothers above 30 years old while about
128 a quarter (26 %) had mothers in the age range of 25 to 29 years (Table 4).

129 There were more HEI who came for Penta 1 (27.7 %) and Measles (27.5 %)
130 vaccinations than those who came for Penta 2 (20.7 %) or Penta 3 (24.1 %). Overall,
131 about 92 percent of all exposed infants were delivered in a health facility. Almost
132 all mothers of exposed babies had tested for HIV (99 %) and had attended three
133 or more ANC visits (90 %) (Table 4). Figure 2 presents the number of HII at
134 national and provincial levels by immunization stage/type the baby came to receive
135 at the time of drawing the sample. A total of 19 HIV positive results were detected
136 in infants who came for Penta 1. Penta 2 and Penta 3 each had 9 babies testing
137 positive to PCR test while Measles had 20.

138 **FIGURE 2 HERE**

139 MTCT Rates in immunization services

140 Of all exposed infants (N=1,409), more male babies (56 percent) were exposed than
141 female babies. Of the 1,409 exposed infants, 1,389 samples were successfully tested
142 for HIV using DNA PCR. A total of 12 samples were rejected and 4 had missing
143 results at the time of study completion. A total of 52 samples were reactive to the
144 PCR test representing an overall rate of transmission of 3.75 percent for infants
145 aged 6 weeks to 9 months. The MTCT rates at 6 weeks, 10 weeks, 14 weeks and
146 9 months were 4.7 percent, 2.8 percent, 2.1 percent and 5.0 percent respectively
147 (Table 3).

148 TABLE 3 HERE

149 The highest proportion of HII was among infants who came to seek Measles vac-
150 cination (36.5 %) at 9 months followed by those who came to seek Penta 1 (27.7%)
151 at 6 weeks. Penta 2 Penta 3 accounted for 15 percent and 14 percent of HII re-
152 spectively. There were more female HII (51.9 %) than male HII (48 %). Slightly
153 over half (51.9%) of all HII were among infants whose mothers were less than 25
154 years old. The majority (80.1 %) HII were delivered in health facilities while about
155 17 percent were delivered at home. The overall number of ANC attendance visits
156 among mothers of HII was high (90.4% had at least 3 ANC visits) and so was
157 reported exclusive breastfeeding (51.9%).

158 TABLE 4 HERE

159 Discussion

160 The study tested the feasibility of infant testing in immunization settings as a
161 technique to determine MTCT rates among infants. The findings indicate that it is
162 feasible, provided adequate resources for supplies (HIV test kits and reagents) are
163 made available to cater for massive tests of all infants in immunization clinics. This
164 will take a strain on existing supplies and will need adequate planning to ensure that
165 all infants in immunization clinics are tested for exposure and all exposed infants
166 are tested for HIV using DNA PCR. The success of the program, as indicated
167 by previous studies will also depend on a strong data capture and documentation
168 system, and robust routine data quality assessment (RDQA)[8, 10, 16, 17, 18].

169 Our study is the first to test the feasibility of this approach to determine MTCT
170 rates in Zambia. However, this method is recommended by the World Health
171 Organisation[19] and has been used and proven to be feasible in Malawi[20] and
172 KwaZulu Natal in South Africa [21]. Our study makes a significant contribution to
173 this growing body of knowledge. The study recruited an even distribution of babies
174 across the four immunization types (Penta 1, Penta 2, Penta 3 and Measles) below
175 the age of one year.

176 The transmission rate at 6 weeks stood at 4.7 percent and was consistent with
177 the 2017 Joint United Nations Programme on HIV/AIDS (UNAIDS) estimate of
178 5 percent. The MTCT rate between 6 weeks and 9 months stood at about 3.75
179 percent, lower than the reported rates in earlier studies1 Copperbelt (4.37 percent)
180 and Lusaka (4.52) provinces had the highest overall proportion of HIV exposed
181 babies who tested positive to HIV. This is in line with the national HIV prevalence
182 trends which are high in Lusaka (15.7 %) and Copperbelt provinces (13.8 %) [14].

183 As expected, the highest rate of vertical transmission was detected among infants
184 who came for Measles vaccination (5.0 %) This was followed by those who came for

185 Penta 1 (4.7 %). It is likely that babies continue to become infected at all stages of
186 immunization. This implies that the risk of infection is continuous and interventions
187 are required throughout the PMTCT cascade until breastfeeding cessation. The
188 majority of infants who tested PCR positive are of mothers below the age of 25
189 years. This is suggestive of the treatment naive mothers who either recently became
190 aware of their status or are struggling to settle in their new sero-status. The study
191 was successful in estimating the MTCT rates for infants below the age of 12 months
192 thus indicating that infant testing in immunization services is a feasible strategy
193 for estimating MTCT rates among the population of HIV exposed infants. Success
194 of this strategy however requires mobilisation of resources and focusing them on
195 inter alia; timely procurement and delivery of infant testing supplies, training on
196 infant testing, timely testing of DBS and communication of results, establishment
197 of robust RDQA to ensure that infant testing data is available on time, complete,
198 accurate, reliable and is of high precision and integrity[22], and improving follow of
199 mother-baby pairs[23].

200 **Conclusion**

201 This study suggests that it feasible to use immunization clinics to monitor both the
202 maternal and infant HIV infections rates and that routine testing in immunization
203 clinics can be used to identify exposed and infected infants early and link them to
204 treatment. Follow-up mechanisms however, need to be put in place to ensure that
205 mother-baby pairs who are not enrolled in the HIV treatment program are tracked
206 and linked to treatment and care. There is further need for routine data quality
207 assessment of PMTCT programme data in all facilities providing PMTCT services.
208 Although this will require increased resources to implement, the long-term cost of
209 estimating MTCT rates and evaluating the effectiveness of the PMTCT program
210 will be reduced.

211 **Abbreviations**

212 ANC: Antenatal Care
213 ART: Antiretroviral treatment
214 BCG: Bacille Calmette Guerin
215 DBS: Dried Blood Spot
216 DNA: Deoxyribonucleic Acid
217 DPTHibHep: Diphtheria, Pertussis, Tetanus, Haemophilus Influenza type B, Hep-
218 atitis B
219 HEI: HIV Exposed Infant
220 HII: HIV Infected Infant
221 HIV: Human Immunodeficiency Virus
222 IPV: inactive Polio Vaccine
223 MTCT: Mother-to-Child Transmission
224 OPV: Oral Polio Vaccine
225 PCR: Polymerase Chain Reaction
226 PCV: Pneumococcal Conjugate Vaccine
227 PMTCT: Prevention of Mother-to-Child Transmission
228 RDQA: Routine Data Quality Assessment Joint United Nations Programme on
229 HIV/AIDS (UNAIDS)

230 **Declarations**

231 **Ethics approval and consent to participate**

232 Ethical approval for the study was sought from the University of Zambia Biomedical Research Ethics Committee
 233 (UNZABREC), a local institutional review board (IRB). Additional approvals were obtained from National Health
 234 Research Authority and the Zambian Ministry of Health at provincial, district and health facility levels. Only children
 235 whose biological parents consented were included in the study. Informed written consent was obtained from the
 236 biological parents of the infants before the interview. Additional written consent was obtained from the biological
 237 parents to draw blood from their infant.

238 **Consent for publication**

239 Not applicable

240 **Competing interests**

241 The authors declare that they have no competing interests.

242 **Funding**

243 The study was supported with funding from Centers for Disease Control and Prevention (CDC). The funding
 244 covered data collection, analysis and report writing.

245 **Availability of data and materials**

246 The datasets used and/or analysed during the current study are available from the corresponding author on
 247 reasonable request.

248 **Author's contributions**

249 JS led on study design, data collection, participated in the data analysis and interpretation of results, prepared the
 250 first draft and participated in later drafts of the article. PF participated in data analysis and interpretation and
 251 drafting of the article. AM participated in data collection, data analysis, interpretation and drafting of the article.
 252 JM participated in the study design, training of data collectors and drafting of the article. CK participated in the
 253 study design and review of the article. All authors have seen and approved the final version.

254 **Acknowledgements**

255 The authors would like to thank all the respondents, health facility staff and District Health Management Teams in
 256 Lusaka, Copperbelt and Southern Provinces who participated in the study. The authors would also like to thank the
 257 Zambian Ministry of Health and the main study funder, CDC. None of the funding organisations were involved in
 258 the analysis/ interpretation of data or the writing of this manuscript.

259 **Author details**

260 ¹Institute of Economic and Social Research (University of Zambia) , Munali Road, 10101 Lusaka, Zambia.
 261 ²Institute of Development and Research, Mosi-oa-Tunya Road, 10101 Lusaka, Zambia. ³Zambia National
 262 HIV/AIDS/TB Council, Independence Avenue, 10101 Lusaka, Zambia. ⁴University Teaching Hospital HIV AIDS
 263 Program (UTH-HAP) , Burma Road, 10101 Lusaka, Zambia.

264 **References**

- 265 1. Torpey, K., Mandala, J., Kasonde, P., Bryan-Mofya, G., Bweupe, M., Mukundu, J.,imba, C., Mwale, C.,
 266 Lumano, H., Welsh, M.: Analysis of hiv early infant diagnosis data to estimate rates of perinatal hiv
 267 transmission in zambia. *PLoS one* **7**(8) (2012)
- 268 2. UNAIDS: Start Free Stay Free AIDS Free 2017 Progress Report. Technical Report UNAIDS/JC2923E, UNAIDS
 269 (2017)
- 270 3. UNICEF: Evaluation of the UNICEF PMTCT / Paediatric HIV Care and Treatment Programme. Technical
 271 report, UNICEF (2017). https://www.unicef.org/evaldatabase/index_95015.html
- 272 4. WHO: HIV/AIDS: Mother-to-Child Transmission of HIV. Technical report, WHO (2019).
 273 <https://www.who.int/hiv/topics/mtct/about/en/>
- 274 5. Ndubani, P., Simbaya, J., Walsh, A., Dicker, P., Kamwanga, J., Brugha, R.: Tracking global hiv/aids initiatives
 275 and their impact on the health system in zambia. Lusaka: University of Zambia/Royal College of Surgeons in
 276 Ireland (2009)
- 277 6. A., A., Waldron, J.: Incremental Cost of Providing Key Services to Prevent Mother-to-Child Transmission
 278 (PMTCT) of HIV in Zambia. Technical report, Futures Group, USAID Health Policy Initiative, Costing Task
 279 Order (2013)
- 280 7. Ministry of Health: Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. Technical
 281 report, Ministry of Health (MOH) [Zambia] (2018)
- 282 8. Mlambo, M.G., Peltzer, K., Koivu, A.: Prevention of mother-to-child transmission of hiv data completeness and
 283 accuracy assessment in health facilities of the nkangala district. *Health SA Gesondheid (Online)* **19**(1), 1–8
 284 (2014)
- 285 9. INESOR: Data Quality Assessment (DQA) Study Report for Development of the Impact Study Protocol on
 286 Prevention of Mother to Child Transmission (PMTCT) in Zambia. Technical report, INESOR/ University of
 287 Zambia (2013)
- 288 10. Moonga, A.M.: Prevention of Mother-to-Child Transmission of HIV Data Quality Assessment in Selected
 289 Health Facilities of the Southern Region of Zambia. (2017).
 290 <https://www.semanticscholar.org/paper/Prevention-of-Mother-to-Child-Transmission-of-HIV:-Moonga/10802d4497a3c99d8a8342bed8110469185cb72a>
- 291 11. Sirengo, M., Rutherford, G.W., Otieno-Nyunya, B., Kellogg, T.A., Kimanga, D., Muraguri, N., Umuro, M.,
 292 Mirjahangir, J., Stein, E., Ndisha, M., et al.: Evaluation of kenya's readiness to transition from sentinel
 293 surveillance to routine hiv testing for antenatal clinic-based hiv surveillance. *BMC infectious diseases* **16**(1), 113
 294 (2016)

296 12. Young, P.W., Mahomed, M., Horth, R.Z., Shiraishi, R.W., Jani, I.V.: Routine data from prevention of
 297 mother-to-child transmission (pmtct) hiv testing not yet ready for hiv surveillance in mozambique: a
 298 retrospective analysis of matched test results. *BMC infectious diseases* **13**(1), 96 (2013)

299 13. Nguéfack, H.L.N., Gwet, H., Desmonde, S., Oukem-Boyer, O.O.M., Nkenfou, C., Téjiokem, M., Tchendjou, P.,
 300 Domkam, I., Leroy, V., Alioum, A., et al.: Estimating mother-to-child hiv transmission rates in cameroon in
 301 2011: a computer simulation approach. *BMC infectious diseases* **16**(1), 11 (2015)

302 14. Ministry of Health: Zambia Population-Based HIV Impact Assessment (ZAMPHIA) 2016: Final Report.
 303 Technical report, Ministry of Health (MOH) [Zambia] (2016). <http://phia.icap.columbia.edu>.

304 15. Central Statistical Office, Zambia and Ministry of Health, Zambia and Tropical Diseases Research Centre,
 305 University of Zambia and Macro International Inc.: Zambia Demographic and Health Survey 2007. Technical
 306 report, Macro International Inc. (2009)

307 16. Rodrigues, J.: Project Heart End of Project report: Tanzania, Eight years of Scaling up HIV Prevention, Care,
 308 and Treatment Services and Savings. Technical report, Elizabeth Glaser Pediatric AIDS Foundation (2012)

309 17. UNAIDS: UNAIDS Report on the Global AIDS Epidemic. Technical report, UNAIDS (2012)

310 18. FHI-360, of Health., B.S.M.: Bayelsa State-wide Rapid Health Facility Assessment. Technical report, FHI 360
 311 and Bayelsa State Ministry of Health (2013)

312 19. WHO: A SHORT GUIDE: Measuring the Impact of National PMTCT Prorammes: Towards the Elimination of
 313 New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive. Technical report, WHO (2012)

314 20. Sinunu, M.A., Schouten, E.J., Wadonda-Kabondo, N., Kajawo, E., Eliya, M., Moyo, K., Chimbwandira, F.,
 315 Strunin, L., Kellerman, S.E.: Evaluating the impact of prevention of mother-to-child transmission of hiv in
 316 malawi through immunization clinic-based surveillance. *PloS one* **9**(6) (2014)

317 21. Rollins, N., Little, K., Mzolo, S., Horwood, C., Newell, M.-L.: Surveillance of mother-to-child transmission
 318 prevention programmes at immunization clinics: the case for universal screening. *Aids* **21**(10), 1341–1347
 319 (2007)

320 22. Idele, P., Hayashi, C., Porth, T., Mamahit, A., Mahy, M.: Prevention of mother-to-child transmission of hiv and
 321 paediatric hiv care and treatment monitoring: from measuring process to impact and elimination of
 322 mother-to-child transmission of hiv. *AIDS and behavior* **21**(1), 23–33 (2017)

323 23. Hamilton, E., Bossiky, B., Ditekemena, J., Esiru, G., Fwamba, F., Goga, A.E., Kieffer, M.P., Tsague, L.D.,
 324 van de Ven, R., Wafula, R., et al.: Using the pmtct cascade to accelerate achievement of the global plan goals.
 325 *Journal of acquired immune deficiency syndromes* (1999) **75**(1), 27 (2017)

326 **Figures**

Figure 1 Infant Sex, HIV Exposure and Vaccination Type. Panel A and B of the figure shows the distribution, in percentage, of sampled infants and HIV exposure by sex. Panel C shows the infant distribution by vaccination type while Panel D shows the infant HIV exposure rate disaggregated by vaccine type and sex.

Figure 2 Number of HIV positive babies by district and infant age/immunization type. The figure shows the number of HIV positive babies by immunization type tested using DNA PCR. The distribution is illustrated at both national level and disaggregated by province.

327 **Tables**

Table 1 Participation Rates

Province	District	Clients	Contacted				Consenting				Refusals	
			For Interviews		For Blood Test		Interview		For Blood Test		n	%
			n	%	n	%	n	%	n	%		
Copperbelt	Ndola	980	965	98.47	950	96.94	15	1.53	30	3.06		
	Kitwe	987	970	98.28	950	96.25	17	1.72	37	3.75		
	Chingola	939	930	99.04	813	86.58	9	0.96	126	13.42		
	Total	2906	2865	98.59	2713	93.36	41	1.41	193	6.64		
Southern	Livingstone	958	940	98.12	939	98.02	18	1.88	19	1.98		
	Choma	1053	1033	98.10	1027	97.53	20	1.90	26	2.47		
	Mazabuka	1105	1051	95.11	994	89.95	54	4.89	111	10.05		
	Total	3116	3024	97.05	2960	94.99	92	2.95	156	5.01		
Lusaka	Lusaka	2500	2400	96.00	2369	94.76	100	4.00	131	5.24		
All		8522	8289	97.27	8042	94.37	233	2.73	480	5.63		

Table 2 Infant HIV exposure by primary caregiver demographic characteristics

	N	%	Infants exposed	% exposed	P-Value
Age of mother					
Less than 25	3,787	47.09	407	10.75	P < 0.001
25-29	1,962	24.4	365	18.60	
30+	2,293	28.5	637	27.78	
Marital Status					
Single	1,303	16.20	194	14.89	P < 0.001
Cohabiting	55	0.68	14	25.45	
Married	6,561	81.58	1,158	17.65	
Divorced	39	0.48	11	28.21	
Separated	57	0.71	17	29.82	
Widowed	27	0.34	15	55.56	
Highest level of Education					
Primary	2,300	28.60	476	20.70	P < 0.001
Secondary	4,991	62.06	793	15.89	
Higher	457	5.68	85	18.60	
None	294	3.66	55	18.71	
Occupation (Employment Status)					
Formal employment	625	7.77	127	20.32	P < 0.001
Self-employed/business	1,899	23.61	403	21.22	
Not employed	5,405	67.21	865	16.00	
School	70	0.87	2	2.86	
Other	43	0.53	12	27.91	
Total	8,042	100	1,409	17.52	

Table 3 Overall MTCT rates by Province and age of infant/immunization type

	Immunization type	Penta 1	Penta 2	Penta 3	Measles	Total
Province	Infant age	6 Weeks	10 Weeks	14 Weeks	9 months	
	Copperbelt Province	2.61	2.91	2.61	6.67	3.85
	Southern Province	4.10	4.40	2.44	2.94	3.36
	Lusaka Province	6.85	1.08	1.05	6.58	4.15
	All	4.70	2.79	2.10	4.99	3.76

Overall MTCT rates calculated as the proportion of PCR positive infants from the number of HIV exposed infants

Table 4 Characteristics of HEI and HII

	HEI	HII	MTCT	P-Value*
Sex				
Male	733 (55 %)	25 (48.0 %)	3.41	P = 0.258
Female	611 (45 %)	27 (51.9 %)	4.42	
All	1344 (100 %)	52 (100 %)	3.87	
Age of mother				
Less than 25	4401 (29.8 %)	27 (51.9 %)	6.73	P = 0.002
25-29	3358 (26.6 %)	9 (17.3 %)	2.51	
30+	625 (46.5 %)	16 (30.8 %)	2.56	
All	1,384 (100 %)	52 (100 %)	3.75	
Current Vaccination				
Penta 1	383 (27.7 %)	18 (34.6 %)	4.70	P=0.115
Penta 2	287 (20.7 %)	8 (15.4 %)	2.79	
Penta 3	333 (24.1 %)	7 (13.5 %)	2.10	
Measles	381 (27.5 %)	19 (36.5 %)	4.99	
All	1,384 (100 %)	52 (100 %)	3.75	
Place of Delivery				
Home	111 (8.0 %)	9 (17.3 %)	8.11	P=0.010
Health Facility	1,269 (91.7 %)	42 (80.8 %)	3.31	
Other	4 (0.3 %)	1 (1.9 %)	25	
All	1,384 (100 %)	52 (100 %)	3.75	
Number of ANC Visits				
None	5 (0.4 %)	0 (0.0 %)	-	P=0.151
1-2	122 (8.9 %)	5 (9.6 %)	4.10	
3	426 (30.9 %)	23 (44.2 %)	5.40	
4	623 (45.2 %)	21 (40.4 %)	3.37	
5+	201 (14.6 %)	3 (5.8 %)	1.49	
All	1,377 (100 %)	52 (100 %)	3.78	
Exclusive Breast Feeding				
Yes	736 (53.2 %)	27 (51.9 %)	3.67	P=0.888
No	648 (46.8 %)	25 (48.0 %)	3.86	
All	1,384 (100 %)	52 (100 %)	3.75	

*Fisher exact test

Figures




Figure 1

Infant Sex, HIV Exposure and Vaccination Type. Panel A and B of the figure shows the distribution, in percentage, of sampled infants and HIV exposure by sex. Panel C shows the infant distribution by vaccination type while Panel D shows the infant HIV exposure rate disaggregated by vaccine type and sex.




Figure 2

Number of HIV positive babies by district and infant age/immunization type. The figure shows the number of HIV positive babies by immunization type tested using DNA PCR. The distribution is illustrated at both national level and disaggregated by province.